BBT-209 / Shaperon, Bridge Biotherap - LARVOL DELTA

Bridge Bio, returns to Chaperone, a candidate for idiopathic pulmonary fibrosis treatment [Google translation] (Health Korea News) - "Bridge Biotherapeutics is returning the idiopathic pulmonary fibrosis (IPF) treatment candidate it had acquired from Chaperone. Bridge Bio announced on the 10th through a public disclosure that it had decided to terminate the technology acquisition contract for the IPF candidate 'BBT-209' with Chaperone. Chaperone is not obligated to return the 2 billion won advance payment it received from Bridge Bio, and Bridge Bio is not obligated to pay additional interim and current technology royalties to Chaperone....BBT-301 plans to enter global phase 2 clinical trials by submitting a US clinical trial plan (IND) in the second half of next year."

IND • Licensing / partnership • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease

Bridge Biotherapeutics Visualizes Pipeline Performance [Google Translation] (Investing.com) - "BBT-877, a treatment for idiopathic pulmonary fibrosis (IPF) that was approved for phase 2 clinical trials by the FDA in July, is expected to begin administration to the first patient within this year and produce interim results in the second half of next year. In addition, the idiopathic pulmonary fibrosis treatment BBT-209 (Shaperon) and BBT-301 (Cellion), whose non-clinical results were disclosed at the IPF Summit, are scheduled to enter phase 1 clinical trials and have abundant research and development momentum."

P2 data • Trial status • Idiopathic Pulmonary Fibrosis

Bridge Biotherapeutics Presented Non-clinical Study Results for 2 IPF Candidates at the IPF Summit 2022 (PRNewswire) - "Bridge Biotherapeutics...presented the non-clinical study results of 'BBT-301', a novel, small molecular inhibitor of KCa 3.1, and 'BBT-209', an endogenous GPCR19 agonist, both being developed as novel IPF treatments, at the 6th Annual IPF Summit (August 29 - September 1, 2022), in Boston, MA....BBT-301 also improved pulmonary function, and attenuated Ashcroft and collagen deposition in bleomycin (BLM)-induced animal model...BBT-209 has exhibited competitive inhibitory effects against cytokine expressions such as IL-1β and TNF-α, with EC50 (effective concentration of 50%) of 0.031 and 0.36 μM each."

Preclinical • Idiopathic Pulmonary Fibrosis • Immunology

Bridge Biotherapeutics first announced two new IPF projects at a conference in the US (Asia Times) - "Bridge Biotherapeutics, at the '2022 IPF Summit' held in Boston, USA, conducted major non-clinical trials of 'BBT-301' and 'BBT-209', new idiopathic pulmonary fibrosis (IPF) treatment candidates. It was announced on the 31st that the data was presented in the form of a poster. Bridge Biotherapeutics unveiled for the first time on the international stage non-clinical data related to drug efficacy and efficacy confirmed in cell lines and animal models for two new candidates under development with different mechanisms of action in IPF."

Preclinical • Idiopathic Pulmonary Fibrosis

Bridge Bio to disclose two idiopathic pulmonary fibrosis data at IPF 2022 (Korea Biomedical Review) - "Bridge Biotherapeutics announced that it would release non-clinical data of idiopathic pulmonary fibrosis (IPF) treatment candidates BBT-301 and BBT-209 at the IPF summit 2022 to be held at Boston from Aug. 29 to Sept. 1....Bridge Bio plans to introduce non-clinical trial research data at the IPF 2022 in a poster format as it has conducted diverse non-clinical trial research after optionally adopting the project from Cellion Biomed in March....'We have decided to disclose non-clinical data at the IPF summit as there are increasing interests of our company’s new pipeline due to the U.S. FDA’s approval for BBT-877 phase 2 clinical trial.'"

Clinical data • Preclinical • Idiopathic Pulmonary Fibrosis

Bridge Biotherapeutics Enters into an Exclusive License Agreement with Shaperon to Strengthen Its IPF Franchise (PRNewswire) - "Bridge Biotherapeutics...today announced that the company has signed an exclusive in-license agreement with Shaperon, a South Korean clinical-stage biotech company, for its GPCR19 (G protein-coupled receptor 19) agonist, coded 'BBT-209', in order to develop a novel therapy for the treatment of idiopathic pulmonary fibrosis (IPF)....By entering into the license agreement, Bridge will make an upfront payment of approximately USD 1.63 million (KRW 2 billion). The potential deal value equates to approximately USD 24.4 million (KRW 30 billion) including upfront, milestone, and royalty payments."

Licensing / partnership • Idiopathic Pulmonary Fibrosis